How Gilead profited by slow-walking a promising HIV therapy

By The New York Times
| July 24, 2023

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...